Most planetary systems contain worlds larger than Earth but smaller than Neptune, and the low-density planets around one ...

Scientists are trying to tame the chaos of modern artificial intelligence by doing something very old fashioned: drawing a ...

Mars is no longer just a story about a single lost ocean or one fleeting window for biology. Taken together, recent rover ...

Hudson Williams and Connor Storrie in 'Heated Rivalry' The Crave gay hockey romance series Heated Rivalry has set screens ablaze with its visceral and intimate sex scenes between the two leads, Hudson ...

Andy Bellatti is a professional astrologer who helps you discover your best self through smart insight and no-nonsense guidance. He runs Astrology with Andy and is available for private readings.

Stock market graphs don’t have to be a mystery. Here’s how to read stock charts for any company. Many, or all, of the products featured on this page are from our advertising partners who compensate us ...

With outstanding customization options, an epic sensor, wireless connectivity, and stunningly lightweight, the Pathfinder is exemplary. Really, it's only mildly let down by its price and the fact that ...

INDIANAPOLIS -- Indianapolis Colts backup quarterback Anthony Richardson suffered an orbital fracture to his eye prior to Sunday's 31-27 victory over the Arizona Cardinals, according to coach Shane ...

There’s something weird in the water in Indianapolis lately. The Colts had a couple of unusual injuries during pregame warmups before Sunday’s win over the Cardinals. Cornerback Charvarius Ward ...

Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...

Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA ...

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...